ORKA

Oruka Therapeutics, Inc.

$12.6

-0.01

(-0.08%)

Exchange:	NASDAQ
Market Cap:	471.75M
Shares Outstanding:

Overview

Earnings

Financials

Valuation

Chart

About The Company

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

Click to read more…

Revenue Segmentation

Error loading revenue segmentation data: No data found for the specified symbol.

Error loading geo segmentation data: No data found for the specified symbol.

EPS

View full analyst estimates

Earnings Call

No transcript or summary available for this symbol.

Income Statement

Balance Sheet

Cash Flow Statement

Analyst Estimates

Income Statement

(* All numbers are in thousands)

No data found.


? Revenue
? Cost Of Revenue
? Gross Profit
? Research And Development Expenses
? General And Administrative Expenses
? Selling And Marketing Expenses
? Operating Expenses
? Net Interest Income
? Interest Income
? Interest Expense
? Depreciation And Amortization
? EBITDA
? EBIT
? Operating Income
? Income Before Tax
? Income Tax Expense
? Net Income From Continuing Operations
? Net Income
? EPS (Earnings Per Share)
? EPS Diluted
? Weighted Average Shares Outstanding
? Weighted Average Shares Outstanding Diluted

Balance Sheet

(* All numbers are in thousands)

No data found.


? Cash And Cash Equivalents
? Short Term Investments
? Cash And Short Term Investments
? Net Receivables
? Accounts Receivables
? Inventory
? Total Current Assets
? Property Plant Equipment Net
? Goodwill
? Intangible Assets
? Long Term Investments
? Total Non Current Assets
? Total Assets
? Account Payables
? Short Term Debt
? Deferred Revenue
? Total Current Liabilities
? Long Term Debt
? Deferred Revenue Non Current
? Deferred Tax Liabilities Non Current
? Total Non Current Liabilities
? Total Liabilities
? Treasury Stock
? Preferred Stock
? Common Stock
? Retained Earnings
? Additional Paid In Capital
? Total Stockholders Equity
? Total Equity
? Minority Interest
? Total Liabilities And Total Equity
? Total Investments
? Total Debt
? Net Debt

Cash Flow Statement

(* All numbers are in thousands)

No data found.


? Net Income
? Depreciation And Amortization
? Deferred Income Tax
? Stock Based Compensation
? Change In Working Capital
? Accounts Receivables
? Inventory
? Accounts Payables
? Net Cash Provided By Operating Activities
? Investments In Property Plant And Equipment
? Acquisitions Net
? Purchases Of Investments
? Sales Maturities Of Investments
? Net Cash Provided By Investing Activities
? Net Debt Issuance
? Long Term Net Debt Issuance
? Short Term Net Debt Issuance
? Net Stock Issuance
? Net Dividends Paid
? Common Dividends Paid
? Preferred Dividends Paid
? Net Cash Provided By Financing Activities
? Effect Of Forex Changes On Cash
? Net Change In Cash
? Cash At End Of Period
? Cash At Beginning Of Period
? Operating Cash Flow
? Capital Expenditure
? Free Cash Flow

Analyst Estimates

(* All numbers are in thousands)

Fiscal Year
Estimated Revenue (Low)
Estimated Revenue (High)
Estimated Revenue (Avg)
Estimated Ebitda (Low)
Estimated Ebitda (High)
Estimated Ebitda (Avg)
Estimated Net Income (Low)
Estimated Net Income (High)
Estimated Net Income (Avg)
Estimated SGA Expense (Low)
Estimated SGA Expense (High)
Estimated SGA Expense (Avg)
Estimated EPS (Avg)
Estimated EPS (High)
Estimated EPS (Low)
Number of Analysts (Estimated Revenue)
Number of Analysts (Estimated EPS)

Subscribe

Log in

Current Key Metrics

?	Revenue (TTM) :	0	?	P/S (TTM) :	0
?	Net Income (TTM) :	-5339000	?	P/E (TTM) :	-6.12
?	Enterprise Value (TTM) :	332.216M	?	EV/FCF (TTM) :	-4.44
?	Dividend Yield (TTM) :	1.75	?	Payout Ratio (TTM) :	0
?	ROE (TTM) :	-0.27	?	ROIC (TTM) :	-0.23
?	Net Debt (TTM) :	-409887000	?	Debt/Equity (TTM) :	0
?	P/B (TTM) :	1.27	?	Current Ratio (TTM) :	30.03